Abstract
Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9% NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.
| Original language | English |
|---|---|
| Pages (from-to) | 55-58 |
| Number of pages | 4 |
| Journal | Journal of Cardiovascular Pharmacology |
| Volume | 24 |
| Issue number | 1 |
| Publication status | Published - 1994 |
Fingerprint
Keywords
- Coronary artery disease
- Diazepam
- Exercise testing
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology
Cite this
Antiischemic effects of intravenous diazepam in patients with coronary artery disease. / Rossetti, Enrico; Fragasso, Gabriele; Xuereb, Robert G.; Xuereb, Mariosa; Margonato, Alberto; Chierchia, Sergio L.
In: Journal of Cardiovascular Pharmacology, Vol. 24, No. 1, 1994, p. 55-58.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiischemic effects of intravenous diazepam in patients with coronary artery disease
AU - Rossetti, Enrico
AU - Fragasso, Gabriele
AU - Xuereb, Robert G.
AU - Xuereb, Mariosa
AU - Margonato, Alberto
AU - Chierchia, Sergio L.
PY - 1994
Y1 - 1994
N2 - Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9% NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.
AB - Diazepam (DZP) is commonly used in treatment of patients with acute ischemic syndromes to allay anxiety, but benzodiazepines reduce myocardial contractility and increase myocardial blood flow. To investigate the antiischemic effect of DZP, we studied 13 patients with a positive exercise test and angiographically documented coronary artery disease. AU patients were submitted to a randomized, placebo-controlled trial using 0.9% NaCI infusion as placebo and intravenous (i.v.) diazepam (0.1 mg/kg in 20 min). Exercise tests performed immediately after the infusions showed that as compared with placebo, DZP significantly prolonged time to I-mm ST-segment depression (557 ± 198 vs. 428 ± 226 s, p <0.0001) and total exercise duration (624 ± 177 vs. 561 ± 188 s, p <0.007). Rate-pressure product (RPP) at 1-mm ST-segment depression was not significantly different with the two treatments. DZP significantly delays onset of exercise-induced myocardial ischemia in patients with coronary artery disease. Because RPP at onset of ischemia was similar to that recorded with placebo despite greater levels of external workload, the antiischemic action of DZP appears to be mediated, at least partially, by a reduction in myocardial oxygen consumption. Key Words: Diazepam-Coronary artery disease-Exercise testing.
KW - Coronary artery disease
KW - Diazepam
KW - Exercise testing
UR - http://www.scopus.com/inward/record.url?scp=0028364799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028364799&partnerID=8YFLogxK
M3 - Article
C2 - 7521490
AN - SCOPUS:0028364799
VL - 24
SP - 55
EP - 58
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
SN - 0160-2446
IS - 1
ER -